Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.62 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.59 |
| ▸ | GRM8 | O00222 | 2/20 | 0.59 |
| ▸ | GRM6 | O15303 | 2/20 | 0.59 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.59 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.59 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.59 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.59 |
| ▸ | GSR | P00390 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.59 |
| ▸ | GRM5 | P41594 | 1/20 | 0.59 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.59 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.59 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.59 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459448 | 1.00 | PTGS1 (0.62) | PTGS1GSTK1SLC1A1GRM8GRM6 | |
| SCHEMBL1769055 | 1.00 | PTGS1 (0.62) | PTGS1GSTK1SLC1A1GRM8GRM6 | |
| SCHEMBL2210613 | 0.96 | PTGS1 (0.59) | PTGS1GSTK1SLC1A1GRM8GRM6 | |
| SCHEMBL6294950 | 0.96 | PTGS1 (0.59) | PTGS1GSTK1SLC1A1GRM8GRM6 | |
| Cysteine SCHEMBL3317768 | 0.91 | PTGS1 (0.67) | PTGS1GSTK1SLC1A1GRM8GRM6 | |
| Norvaline SCHEMBL2178341 | 0.91 | PTGS1 (0.55) | PTGS1GSTK1SLC1A1GRM8GRM6 | |
| SCHEMBL31207012 | 0.86 | PTGS1 (0.49) | PTGS1GSTK1SLC1A1GRM8GRM6 | |
| SCHEMBL16203683 | 0.86 | PTGS1 (0.56) | PTGS1GSTK1SLC1A1GRM8GRM6 | |
| SCHEMBL10136169 | 0.85 | SLC1A1 (0.50) | PTGS1GSTK1SLC1A1GRM8GRM6 | |
| SCHEMBL9716241 | 0.85 | SLC1A1 (0.50) | PTGS1GSTK1SLC1A1GRM8GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| CN-114269951-B | Diagnostic method for aesthetic deterioration of skin | 欧莱雅 | 2024-12-27 | — | — | CN | claimed |
| US-12050228-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2024-07-30 | — | — | US | claimed |
| CN-118311265-A | Metabolic molecular marker for differential diagnosis of diabetes after chronic pancreatitis | 东南大学附属中大医院 | 2024-07-09 | — | — | CN | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| US-20230003740-A1 | METHOD FOR DIAGNOSING ESTHETIC DEGRADATIONS OF SKIN | L'OREAL (FR) | 2023-01-05 | — | — | US | claimed |
| EP-3987064-A1 | METHOD FOR DIAGNOSING ESTHETIC DEGRADATIONS OF SKIN | L'OREAL (FR) | 2022-04-27 | — | — | EP | claimed |
| CN-114269951-A | Diagnostic method for aesthetic deterioration of skin | 欧莱雅 | 2022-04-01 | — | — | CN | claimed |
| EP-3796976-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | Epitracker, Inc. (US) | 2021-03-31 | — | — | EP | claimed |
| US-20210088539-A1 | AUTOMATED SAMPLE QUALITY ASSESSMENT | METABOLON, INC. | 2021-03-25 | — | — | US | claimed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | claimed |
| WO-2020260355-A1 | METHOD FOR DIAGNOSING ESTHETIC DEGRADATIONS OF SKIN | L'OREAL (FR) | 2020-12-30 | — | — | WO | claimed |
| EP-0266905-A1 | Reagents for assay of gamma-glutamyl-transpeptidase | UNITIKA LTD. (JP) | 1988-05-11 | — | — | EP | claimed |
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | EPITRACKER INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| EP-2501715-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | Polyphor Ag (CH) | 2012-09-26 | — | — | EP | disclosed |
| WO-2011060937-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY | POLYPHOR AG (CH) | 2011-05-26 | — | — | WO | disclosed |
| EP-0266905-B1 | REAGENTS FOR ASSAY OF GAMMA-GLUTAMYL-TRANSPEPTIDASE | UNITIKA LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0266905-A1 | Reagents for assay of gamma-glutamyl-transpeptidase | UNITIKA LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137646-A1 | PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITY | HTR6, HTR2A, OPRL1 | PTGS1 1366/4885GSTK1 2253/4885SLC1A1 499/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | PTGS1 2631/4885GSTK1 3627/4885SLC1A1 149/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | PTGS1 2333/4885GSTK1 3525/4885SLC1A1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.